Hyderabad News Desk

The Anemia In Chronic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Anemia In Chronic Kidney Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anemia In Chronic Kidney Disease Market.

Some of the key takeaways from the Anemia In Chronic Kidney Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Anemia In Chronic Kidney Disease treatment therapies with a considerable amount of success over the years. 
• Anemia In Chronic Kidney Disease companies working in the treatment market are Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Genexine, and others, are developing therapies for the Anemia In Chronic Kidney Disease treatment 

• Emerging Anemia In Chronic Kidney Disease therapies in the different phases of clinical trials are- DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others are expected to have a significant impact on the Anemia In Chronic Kidney Disease market in the coming years.   
• In April 2023, Genexine and its Asian regional partner, KG Bio unveiled the interim results of Phase 3 clinical trial of GX-E4 (Efepoetin alfa), a candidate for CKD (Chronic Kidney Disease) induced anemia. Its noninferiority results compared to Mircera (Methoxy Polyethylene Glycol-epoetin beta) were presented at theWorld Congress of Nephrology (WCN2023).
• In July 2020, Genexine initiated an open-label randomised controlled trial of efepoetin alfa fortreatment of anaemia associated with chronic kidney disease patients not on dialysis (ND-CKD). a non- inferioritytrial compared to methoxy polyethylene glycol-epoetin beta (MIRCERA).

Anemia In Chronic Kidney Disease Overview

Anemia is a common complication of chronic kidney disease (CKD). CKD means the kidneys are damaged and can’t filterblood the way they should. This damage can cause waste and fluid to build up in the body. CKD can also cause other healthproblems.

Get a Free Sample PDF Report to know more about Anemia In Chronic Kidney Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-pipeline-insight

Emerging Anemia In Chronic Kidney Disease Drugs Under Different Phases of Clinical Development Include:

• DDO-3055: Jiangsu HengRui Medicine
• DISC 0974: Disc Medicine
• SSS 17: 3SBio
• AND017: Kind Pharmaceuticals
• Pegol-Sihematide: Jiangsu Hansoh Pharmaceutical
• Efepoetin alfa: Genexine

Anemia In Chronic Kidney Disease Route of Administration

Anemia In Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Anemia In Chronic Kidney Disease Molecule Type

Anemia In Chronic Kidney Disease Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Anemia In Chronic Kidney Disease Pipeline Therapeutics Assessment

• Anemia In Chronic Kidney Disease Assessment by Product Type
• Anemia In Chronic Kidney Disease By Stage and Product Type
• Anemia In Chronic Kidney Disease Assessment by Route of Administration
• Anemia In Chronic Kidney Disease By Stage and Route of Administration
• Anemia In Chronic Kidney Disease Assessment by Molecule Type
• Anemia In Chronic Kidney Disease by Stage and Molecule Type

DelveInsight’s Anemia In Chronic Kidney Disease Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Anemia In Chronic Kidney Disease product details are provided in the report. Download the Anemia In Chronic Kidney Disease pipeline report to learn more about the emerging Anemia In Chronic Kidney Disease therapies

Some of the key companies in the Anemia In Chronic Kidney Disease Therapeutics Market include:

Key companies developing therapies for Anemia In Chronic Kidney Disease are – 3SBio Inc, Japan Tobacco Inc, Akebia Therapeutics Inc, GSK plc, UBI Pharma Inc, Xenetic Biosciences Inc, Zydus Lifesciences Ltd, and Avesthagen Ltd, and others.

Anemia In Chronic Kidney Disease Pipeline Analysis:

The Anemia In Chronic Kidney Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Anemia In Chronic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anemia In Chronic Kidney Disease Treatment.
• Anemia In Chronic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Anemia In Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anemia In Chronic Kidney Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Anemia In Chronic Kidney Disease drugs and therapies

Anemia In Chronic Kidney Disease Pipeline Market Drivers

Increase in the geriatric population with a higher risk of renal anemia due to age-related renal issues, increase in research and developmental activities are some of the important factors that are fueling the Anemia In Chronic Kidney Disease Market.

Anemia In Chronic Kidney Disease Pipeline Market Barriers

However, high-cost associated with the disease, side effects associated with the disease  and other factors are creating obstacles in the Anemia In Chronic Kidney Disease Market growth.

Scope of Anemia In Chronic Kidney Disease Pipeline Drug Insight    

• Coverage: Global
• Key Anemia In Chronic Kidney Disease Companies: Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Genexine, and others
• Key Anemia In Chronic Kidney Disease Therapies: DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others
• Anemia In Chronic Kidney Disease Therapeutic Assessment: Anemia In Chronic Kidney Disease current marketed and Anemia In Chronic Kidney Disease emerging therapies
• Anemia In Chronic Kidney Disease Market Dynamics: Anemia In Chronic Kidney Disease market drivers and Anemia In Chronic Kidney Disease market barriers 

Request for Sample PDF Report for Anemia In Chronic Kidney Disease Pipeline Assessment and clinical trials

Table of Contents

1. Anemia In Chronic Kidney Disease Report Introduction

2. Anemia In Chronic Kidney Disease Executive Summary

3. Anemia In Chronic Kidney Disease Overview

4. Anemia In Chronic Kidney Disease- Analytical Perspective In-depth Commercial Assessment

5. Anemia In Chronic Kidney Disease Pipeline Therapeutics

6. Anemia In Chronic Kidney Disease Late Stage Products (Phase II/III)

7. Anemia In Chronic Kidney Disease Mid Stage Products (Phase II)

8. Anemia In Chronic Kidney Disease Early Stage Products (Phase I)

9. Anemia In Chronic Kidney Disease Preclinical Stage Products

10. Anemia In Chronic Kidney Disease Therapeutics Assessment

11. Anemia In Chronic Kidney Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Anemia In Chronic Kidney Disease Key Companies

14. Anemia In Chronic Kidney Disease Key Products

15. Anemia In Chronic Kidney Disease Unmet Needs

16 . Anemia In Chronic Kidney Disease Market Drivers and Barriers

17. Anemia In Chronic Kidney Disease Future Perspectives and Conclusion

18. Anemia In Chronic Kidney Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services